Juan María Blanco Madrigal-rekin lankidetzan egindako argitalpenak (3)

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

2021

  1. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: Data from the BIOBADASER III register

    Arthritis Research and Therapy, Vol. 22, Núm. 1